A Lack of Effectiveness in the ATM-Orchestrated DNA Damage Response Contributes to the DNA Repair Defect of HPV-Positive Head and Neck Cancer Cells.

DNA damage response (DDR) DNA double-strand break repair ataxia telangiectasia mutated (ATM) head and neck cancer human papillomavirus (HPV) radiation sensitivity

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 27 08 2021
accepted: 25 04 2022
entrez: 20 6 2022
pubmed: 21 6 2022
medline: 21 6 2022
Statut: epublish

Résumé

Patients with human papillomavirus-positive squamous cell carcinoma of the head and neck (HPV+ HNSCC) have a favorable prognosis compared to those with HPV-negative (HPV-) ones. We have shown previously that HPV+ HNSCC cell lines are characterized by enhanced radiation sensitivity and impaired DNA double-strand break (DSB) repair. Since then, various publications have suggested a defect in homologous recombination (HR) and dysregulated expression of DSB repair proteins as underlying mechanisms, but conclusions were often based on very few cell lines. When comparing the expression levels of suggested proteins and other key repair factors in 6 HPV+ vs. 5 HPV- HNSCC strains, we could not confirm most of the published differences. Furthermore, HPV+ HNSCC strains did not demonstrate enhanced sensitivity towards PARP inhibition, questioning a general HR defect. Interestingly, our expression screen revealed minimal levels of the central DNA damage response kinase ATM in the two most radiosensitive HPV+ strains. We therefore tested whether insufficient ATM activity may contribute to the enhanced cellular radiosensitivity. Irrespective of their ATM expression level, radiosensitive HPV+ HNSCC cells displayed DSB repair kinetics similar to ATM-deficient cells. Upon ATM inhibition, HPV+ cell lines showed only a marginal increase in residual radiation-induced γH2AX foci and induction of G2 cell cycle arrest as compared to HPV- ones. In line with these observations, ATM inhibition sensitized HPV+ HNSCC strains less towards radiation than HPV- strains, resulting in similar levels of sensitivity. Unexpectedly, assessment of the phosphorylation kinetics of the ATM targets KAP-1 and Chk2 as well as ATM autophosphorylation after radiation did not indicate directly compromised ATM activity in HPV-positive cells. Furthermore, ATM inhibition delayed radiation induced DNA end resection in both HPV+ and HPV- cells to a similar extent, further suggesting comparable functionality. In conclusion, DNA repair kinetics and a reduced effectiveness of ATM inhibition clearly point to an impaired ATM-orchestrated DNA damage response in HPV+ HNSCC cells, but since ATM itself is apparently functional, the molecular mechanisms need to be further explored.

Identifiants

pubmed: 35719921
doi: 10.3389/fonc.2022.765968
pmc: PMC9204973
doi:

Types de publication

Journal Article

Langues

eng

Pagination

765968

Informations de copyright

Copyright © 2022 Köcher, Zech, Krug, Gatzemeier, Christiansen, Meyer, Rietow, Struve, Mansour, Kriegs, Petersen, Betz, Rothkamm and Rieckmann.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cancer Res. 2022 Mar 01;82(5):916-928
pubmed: 34965932
Radiother Oncol. 2022 Mar;168:138-146
pubmed: 35093407
Annu Rev Cancer Biol. 2018 Mar;2:313-336
pubmed: 30345412
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
J Clin Oncol. 2009 Apr 20;27(12):1992-8
pubmed: 19289615
Cancer Res. 2004 Jan 15;64(2):500-8
pubmed: 14744762
PLoS One. 2018 Dec 13;13(12):e0207934
pubmed: 30543656
Nucleic Acids Res. 2015 Mar 31;43(6):3154-66
pubmed: 25753674
Mol Cell. 2013 May 23;50(4):589-600
pubmed: 23706822
Cancer Biomark. 2022;33(3):331-347
pubmed: 34542062
Genes Dev. 2016 Nov 15;30(22):2500-2512
pubmed: 27940962
Mol Cell. 2008 Jul 25;31(2):167-77
pubmed: 18657500
Viruses. 2017 Sep 21;9(10):
pubmed: 28934154
Oncogene. 2017 Feb 9;36(6):820-828
pubmed: 27425591
PLoS Genet. 2013;9(2):e1003277
pubmed: 23468639
Cancer Res. 2014 Mar 15;74(6):1739-51
pubmed: 24473065
Mol Cell. 2017 Jun 15;66(6):801-817
pubmed: 28622525
Radiother Oncol. 2013 Jan;106(1):147-54
pubmed: 23199656
Radiother Oncol. 2014 Dec;113(3):317-23
pubmed: 25480095
Radiother Oncol. 2011 Jun;99(3):307-12
pubmed: 21680038
Nucleic Acids Res. 2012 Sep 1;40(17):8336-47
pubmed: 22730303
Clin Cancer Res. 2012 Mar 1;18(5):1257-67
pubmed: 22247495
Cancers (Basel). 2020 Jun 07;12(6):
pubmed: 32517381
Recent Results Cancer Res. 2021;217:141-155
pubmed: 33200365
Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5564-9
pubmed: 23509290
Ann Oncol. 2019 Sep 1;30(9):1437-1447
pubmed: 31218365
Clin Cancer Res. 2018 Dec 1;24(23):6001-6014
pubmed: 30087144
Cell. 2018 May 3;173(4):972-988.e23
pubmed: 29656893
Cancers (Basel). 2021 Jul 23;13(15):
pubmed: 34359617
Radiother Oncol. 2012 Apr;103(1):49-56
pubmed: 22410204
Radiother Oncol. 2013 May;107(2):242-6
pubmed: 23602369
Front Oncol. 2021 Jul 20;11:683688
pubmed: 34354944
PLoS Pathog. 2009 Oct;5(10):e1000605
pubmed: 19798429
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Mol Cancer Res. 2014 Nov;12(11):1597-609
pubmed: 25103497
EMBO J. 2009 Nov 4;28(21):3413-27
pubmed: 19779458
Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19552-19562
pubmed: 31501315
Oncotarget. 2015 Sep 29;6(29):26995-7007
pubmed: 26336991
Genes (Basel). 2021 Aug 31;12(9):
pubmed: 34573351
Nucleic Acids Res. 2008 Jul;36(12):4088-98
pubmed: 18539610
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Oncotarget. 2017 Oct 24;8(62):105170-105183
pubmed: 29285242
Curr Eye Res. 2021 Apr;46(4):546-557
pubmed: 32862699
Environ Mol Mutagen. 2015 Jul;56(6):491-504
pubmed: 25773265
Virus Res. 2017 Mar 2;231:41-49
pubmed: 27836727
Oncotarget. 2017 May 2;8(18):29963-29975
pubmed: 28415784
Int J Mol Sci. 2020 Dec 01;21(23):
pubmed: 33271982
J Biol Chem. 2013 Mar 8;288(10):7086-95
pubmed: 23355489
Int J Cancer. 2020 Feb 15;146(4):1075-1085
pubmed: 31283004
Mol Cell Biol. 2002 Feb;22(4):1049-59
pubmed: 11809797
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21573-21579
pubmed: 31591214
Cancer Lett. 2019 Sep 28;460:75-85
pubmed: 31247272
EMBO J. 2000 Feb 1;19(3):463-71
pubmed: 10654944
Cell Rep. 2015 Mar 31;10(12):2006-18
pubmed: 25818292
Infect Agent Cancer. 2021 Aug 13;16(1):56
pubmed: 34389030
Cancer Res. 2013 Aug 1;73(15):4791-800
pubmed: 23749640
Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):7665-7670
pubmed: 28659469
Br J Cancer. 2016 Sep 27;115(7):825-30
pubmed: 27584664
J Virol. 2017 Sep 27;91(20):
pubmed: 28768872
Mol Cell. 2004 Dec 3;16(5):715-24
pubmed: 15574327

Auteurs

Sabrina Köcher (S)

Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Henrike Barbara Zech (HB)

Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mildred-Scheel Cancer Career Center HaTriCS, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Leonie Krug (L)

Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Fruzsina Gatzemeier (F)

Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Sabrina Christiansen (S)

Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Felix Meyer (F)

Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Ruth Rietow (R)

Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Research Department, Cell and Gene Therapy, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Nina Struve (N)

Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mildred-Scheel Cancer Career Center HaTriCS, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Wael Yassin Mansour (WY)

Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mildred-Scheel Cancer Career Center HaTriCS, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Malte Kriegs (M)

Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Cordula Petersen (C)

Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Christian Betz (C)

Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Kai Rothkamm (K)

Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Thorsten Rieckmann (T)

Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Classifications MeSH